Prognostic studies of canine and feline mammary tumours: The need for standardized procedures

Veterinary Journal

Volumn 193, Issue 1, 2012, Pages 24-31

  Matos, A J F ^a   Baptista, C S ^a,b   Gartner M F ^a   Rutteman, G R ^c,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^c UTRECHT UNIVERSITY   (Netherlands)

^d Specialist Veterinary Centre De Wagenrenk   (Netherlands)

Author keywords

Canine; Comparative oncology; Feline; Mammary tumours; Prognostic studies; Standardization

Indexed keywords

BREAST METASTASIS; BREAST TUMOR; CANCER GRADING; CANCER INFILTRATION; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CAT; DISEASE FREE INTERVAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DOG; FOLLOW UP; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MASTECTOMY; MICROMETASTASIS; NONHUMAN; PREDICTIVE VALUE; REVIEW; TUMOR CLASSIFICATION; TUMOR VOLUME;

ANIMALS; CAT DISEASES; CATS; DOG DISEASES; DOGS; FEMALE; MAMMARY NEOPLASMS, ANIMAL; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; REPRODUCIBILITY OF RESULTS; VETERINARY MEDICINE;

CANIS FAMILIARIS; FELIDAE;

EID: 84863782362     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2011.12.019     Document Type: Review

References (75)

1. Allen S., Mahaffey E. Canine mammary neoplasia: Prognostic indicators and response to surgical therapy. Journal of the American Animal Hospital Association 1989, 25:540-546.
2. Allen S.W., Prasse K.W., Mahaffey E.A. Cytologic differentiation of benign from malignant canine mammary tumors. Veterinary Pathology 1986, 23:649-655.
3. Andea A.A., Wallis T., Newman L.A., Bowman D., Dev J., Visscher D.W. Pathologic analysis of tumour size and lymph node status in multifocal/multicentric breast carcinoma. Cancer 2002, 94:1383-1390.
4. Baptista C.S., Bastos E., Santos S., Gut I.G., Guedes-Pinto H., Gärtner F., Chaves R. TWIST1 gene: First insights in Felis catus. Current Genomics 2010, 11:212-220.
5. Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER-2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer Registry. Cancer 2007, 109:1721-1728.
6. Beveridge W.I.B., Sobin L.H. Introduction. In: International histological classification of tumours in domestic animals. Bulletin of the World Health Organization 1974, 50:1-3.
7. Bostock D.E. The prognosis following the surgical excision of canine mammary neoplasms. European Journal of Cancer 1975, 11:389-396.
8. Cassali G.D., Gobbi H., Malm C., Schmitt F.C. Evaluation of accuracy of fine needle aspiration cytology for diagnosis of canine mammary tumours: Comparative features with human tumours. Cytopathology 2007, 18:191-196.
9. Castagnaro M., Casalone C., Bozzetta E., De Maria R., Biolatti B., Caramelli M. Tumour grading and the one-year post-surgical prognosis in feline mammary carcinomas. Journal of Comparative Pathology 1998, 119:263-275.
10. Davoli A., Hocevar B.A., Brown T.L. Progression and treatment of HER2-positive breast cancer. Cancer Chemotherapy and Pharmacology 2010, 65:611-623.
11. De las Mulas J., Millán Y., Dios R. A prospective analysis of immunohistochemically determined estrogen receptor α and progesterone receptor expression and host and tumour factors as predictors of disease-free period in mammary tumours of the dog. Veterinary Pathology 2005, 42:200-212.
12. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., Dancey J., Arbuck S., Gwyther S., Mooney M., Rubinstein L., Shankar L., Dodd L., Kaplan R., Lacombe D., Verweij J. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer 2009, 45:228-247.
13. Farrand K., Jovanovic L., Delahunt B., McIver B., Hay I.D., Eberhardt N.L., Grebe S.K. Loss of heterozygosity studies revisited: Prior quantification of the amplifiable DNA content of archival samples improves efficiency and reliability. Journal of Molecular Diagnostics 2002, 4:150-158.
14. Fitzgibbons P.L., Page D.L., Weaver D., Thor A.D., Allred D.C., Clark G.M., Ruby S.G., O'Malley F., Simpson J.F., Connolly J.L., Hayes D.F., Edge S.B., Lichter A., Schnitt S.J. Prognostic factors in breast cancer. American Pathologists Consensus Statement 1999. Archives of Pathology & Laboratory Medicine 2000, 124:966-978.
15. Fox L., MacEwen E.G., Kurzman I.D., Dubielzing R.R., Helfand S.C., Vail D.M., Kisseberth W., London C., Madewell B.R., Rodriguez C.O. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma: A multicenter randomized double-blind study. Cancer Biotherapy 1995, 10:125-130.
16. Gama A., Alves A., Schmitt F. Identification of molecular phenotypes in canine mammary carcinomas with clinical implications: Application of the human classification. Virchows Archive 2008, 453:123-132.
17. Gilbertson S.R., Kurzman I.D., Zachrau R.E., Hurvitz A.I., Black M.M. Canine mammary epithelial neoplasms: Biologic implications of morphologic characteristics assessed in 232 dogs. Veterinary Pathology 1983, 20:127-142.
18. Goldschmidt M., Peña L., Rasotto R., Zappulli V. Classification and grading of canine mammary tumors. Veterinary Pathology 2011, 48:117-131.
19. Györffy B., Schäfer R. Meta-analysis of gene expression profiles related to relapse-free survival in 1079 breast cancer patients. Breast Cancer Research and Treatment 2009, 118:433-441.
20. Hampe J.F., Misdorp W. Tumours and dysplasias of the mammary gland. Bulletin of the World Health Organization 1974, 50:111-133.
21. Hellmén E., Lindgren A., Linell F., Matsson P., Nilsson A. Comparison of histology and clinical variables to DNA ploidy in canine mammary tumors. Veterinary Pathology 1988, 25:219-226.
22. Hellmén E., Bergström R., Holmberg L., Spångberg I.-B., Hansson K., Lindgren A. Prognostic factors in canine mammary tumors: A multivariate study of 202 consecutive cases. Veterinary Pathology 1993, 30:20-27.
23. Imyanitov E.N., Grigoriev M.Y., Gorodinskaya V.M., Kuligina E.S., Pozharisski K.M., Togo A.V., Hanson K.P. Partial restoration of degraded DNA from archival paraffin-embedded tissues. Biotechniques 2002, 31:1000-1002.
24. Ito T., Kadosawa T., Mochizuki M., Matsunaga S., Nishimura R., Sasaki N. Prognosis of malignant mammary tumor in 53 cats. Journal of Veterinary Medical Science 1996, 58:723-726.
25. Itoh T., Uchida K., Ishikawa K., Kushima K., Kushima E., Tamada H., Moritake T., Nakao H., Shii H. Clinicopathological Survey of 101 canine mammary gland tumours: Differences between small-breed dogs and others. Journal of Veterinary Medical Science 2005, 67:345-347.
26. Karayannopoulou M., Kaldrymidou E., Constantinidis T., Dessiris A. Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and doxetacel. Journal of Veterinary Internal Medicine 2001, 20:1184-1190.
27. Karayannopoulou M., Kaldrymidou E., Constantinidis T.C., Dessiris A. Histological grading and prognosis in dogs with mammary carcinomas: Application of a human grading method. Journal of Comparative Pathology 2005, 133:246-252.
28. Lana S.E., Rutteman G.R., Withrow S.J. Tumors of the mammary gland. Small Animal Clinical Oncology 2007, 619-636. Saunders Elsevier, St. Louis, MO, USA. Fourth Ed.
29. Lin J., Kennedy S.H., Svarovsky T., Rogers J., Kemnitz J.W., Xu A., Zondervan K.T. High-quality genomic DNA extraction from formalin-fixed and paraffin-embedded samples deparaffinized using mineral oil. Analytical Biochemistry 2009, 395:265-267.
30. MacEwen E.G., Hayes A.A., Mooney S., Patnaik A.K., Harvey H.J., Passe S., Hardy W.D. Evaluation of effect of levamisole on feline mammary cancer. Journal of Biological Response Modifiers 1984, 5:541-546.
31. MacEwen E.G., Hayes A.A., Harvey H.J., Patnaik A.K., Mooney S., Passe S. Prognostic factors for feline mammary tumours. Journal of the American Veterinary Medical Association 1984, 185:201-204.
32. MacEwen E.G., Harvey H.J., Patnaik A.K., Mooney S., Hayes A., Kurzman I., Hardy W.D. Evaluation of effects of levamisole and surgery on canine mammary cancer. Journal of Biological Response Modifiers 1985, 4:418-426.
33. Matos A.J.F., Faustino A.M.R., Lopes C., Rutteman G.R., Gärtner F. Detection of lymph node micrometastases in malignant mammary tumours in dogs by cytokeratin immunostaining. Veterinary Record 2006, 158:626-629.
34. Matos A.J.F., Lopes C., Carvalheira J., Santos M., Rutteman G.R., Gärtner F. E-cadherin expression in canine malignant mammary tumours: Relationship to other clinic-pathological variables. Journal of Comparative Pathology 2006, 134:182-189.
35. Misdorp W., Hart A.A. Prognostic factors in canine mammary cancer. Journal of the National Cancer Institute 1976, 56:779-786.
36. Misdorp W., Hart A.A.M. Canine mammary cancer. II: Therapy and causes of death. Journal of Small Animal Practice 1979, 20:395-404.
37. Misdorp, W., Else, R.W., Hellmén, E., Lipscomb, T.P., 1999. Histological Classification of Mammary Tumors of the Dog and the Cat. World Health Organization Histological Classification of Tumors of Domestic Animals, Second Series, vol. 7, no. 2. Washington, Armed Forces Institute of Pathology, DC.
38. Moller K., Rinke J., Ross A., Buddle G., Brimacombe R. The use of formaldehyde in RNA-protein cross-linking studies with ribosomal subunits from Escherichia coli. European Journal of Biochemistry 1977, 76:175-187.
39. Morris J., Dobson J., Bostock D. Use of tamoxifen in the control of canine mammary neoplasia. Veterinary Record 1993, 27:539-542.
40. Morris J.S., Dobson J.M., Bostock D.E., O'Farrell E. Effect of ovariohysterectomy in bitches with mammary neoplasms. Veterinary Record 1998, 142:656-658.
41. Mutter G.L., Zahrieh D., Liu C., Neuberg D., Finkelstein D., Baker H.E., Warringtom J.A. Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays. BMC Genomics 2004, 5:88-94.
42. Narod S.A. Age of diagnosis, tumor size and survival of the breast cancer: Implications for mammographic screening. Breast Cancer Research and Treatment 2011, 28:259-266.
43. Nieto A.I., Peña L., Pérez-Alenza M.D., Sánchez M.A., Flores J.M., Castaño M. Immunohistologic detection of estrogen receptor alpha in canine mammary tumors: Clinical and pathologic associations and prognostic significance. Veterinary Pathology 2000, 37:239-247.
44. Novosad C.A., Bergman P.J., O'Brien M.G., McKnight J.A., Charney S.C., Selting K.A., Graham J.C., Correa S.S., Rosenberg M.P., Gieger T.L. Retrospective evaluation of adjunctive doxorubicin for the treatment of feline mammary gland adenocarcinoma: 67 cases. Journal of the American Animal Hospital Association 2006, 42:110-120.
45. Overley B., Shofer F.S., Goldschmidt M.H., Sherer D., Sorenmo K.U. Association between ovarihysterectomy and feline mammary carcinoma. Journal of Veterinary Internal Medicine 2005, 19:560-563.
46. Owen L.N. Classification of Tumors in Domestic Animals 1980, World Health Organization, Geneva, pp. 1-54. First Ed.
47. Pang L.Y., Argyle D.J. Using naturally occurring tumours in dogs and cats to study telomerase and cancer stem cell biology. Biochimica et Biophysica Acta 2009, 1792:380-391.
48. Paoloni M., Khanna C. Translation of new cancer treatments from pet dogs to humans. Nature 2008, 8:147-156.
49. Parodi A.L., Misdorp W., Mialot J.P., Mialot M., Hart A.A., Hurtrel M., Salomon J.C. Intratumoral BCG and Corynebacterium Parvum therapy of canine mammary tumors before radical mastectomy. Cancer Immunology and Immunotherapy 1983, 15:172-177.
50. Patani N., Mokbel K. The clinical significance of sentinel lymph node micrometastasis in breast cancer. Breast Cancer Research and Treatment 2009, 114:393-402.
51. Peña L.L., Nieto A.I., Pérez-Alenza D., Cuesta P., Castaño M. Immunohistochemical detection of Ki-67 and PCNA in canine mammary tumors: Relationship to clinical and pathologic variables. Journal of Veterinary Diagnostic Investigation 1998, 10:237-246.
52. Pérez-Alenza M.D., Peña L., Nieto A.I., Castaño M. Clinical and pathological prognostic factors in canine mammary tumors. Annali dell'Istituto superiore di sanità 1997, 33:581-585.
53. Philibert J.C., Snyder P.W., Glickman N., Glickman L.T., Knapp D.W., Waters D.J. Influence of host factors on survival in dogs with malignant mammary gland tumors. Journal of Veterinary Internal Medicine 2003, 17:102-106.
54. Poljak M., Seme K., Gale N. Rapid extraction of DNA from archival clinical specimens: Our experiences. Pflügers Archiv: European Journal of Physiology 2000, 439:R42-R44.
55. Rivera P., von Euler H. Molecular biological aspects on canine and human mammary tumours. Veterinary Pathology 2011, 48:132-146.
56. Rutteman G.R., Cornelisse C.J., Dijkshoorn N.J., Poortman J., Misdorp W. Flow cytometric analysis of DNA ploidy in canine mammary tumors. Cancer Research 1988, 48:3411-3417.
57. Rutten V., Misdorp W., Gauthier A., Estrada M., Mialot J.P., Parodi A.L., Rutteman G.R., Weyer K. Immunological aspects of mammary tumors in dogs and cats: A survey including own studies and pertinent literature. Veterinary Immunology and Immunopathology 1990, 26:211-225.
58. Sassi F., Benazzi C., Castellani G., Sarli G. Molecular-based tumour subtypes of canine mammary carcinomas assessed by immunohistochemistry. BMC Veterinary Research 2010, 6:5.
59. Seixas F., Palmeira C., Pires M.A., Bento M.J., Lopes C. Grade is an independent prognostic factor for feline mammary carcinomas: A clinicopathological and survival analysis. The Veterinary Journal 2011, 187:65-71.
60. Shofer F.S., Sonnenshein E.G., Goldschmidt M.H., Laster L.L., Glickman L.T. Histopathologic and dietary prognostic factors for canine mammary carcinoma. Breast Cancer Research and Treatment 1989, 13:49-60.
61. Simon D., Schoenrock D., Baumgärtner W., Nolte I. Postoperative adjuvant treatment of invasive malignant mammary gland tumors in dogs with doxorubicin and docetaxel. Journal of Veterinary Internal Medicine 2006, 20:1184-1190.
62. Singletary S.A., Conolly J.L. Breast cancer staging: Working with the sixth edition of the AJCC Cancer Staging System. CA: A Cancer Journal for Clinicians 2006, 56:37-47.
63. Singletary S.A., Allred C., Ashley P., Bassett L.W., Berry D., Bland K.I., Borgen P.I., Clark G., Edge S.B., Hayes D.F., Hughes L.L., Hutter R.V.P., Morrow M., Page D.L., Recht A., Theriault R.L., Thor A., Weaver D.L., Wieand H.S., Greene F.L. Revision of the American Joint Committee on Cancer Staging System for breast cancer. Journal of Clinical Oncology 2002, 20:3628-3636.
64. Sobin L.H., Wittekind C.H. TNM Classification of Malignant Tumours 2002, UICC, Wiley-Liss, New York. Sixth Ed.
65. Sorenmo K.U., Shofer F.S., Goldschmidt M.H. Effect of spaying and timing of spaying on survival of dogs with mammary carcinoma. Journal of Veterinary Internal Medicine 2000, 14:266-270.
66. Stratman N., Failing K., Richter A., Wehrend A. Mammary tumour recurrence in bitches after regional mastectomy. Veterinary Surgery 2008, 37:82-86.
67. Teske E., Rutteman G.R., vd Ingh T.S., van Noort R., Misdorp W. Liposome-encapsulated muramyl tripeptide phosphatidyl-ethanolamine (L-MTP-PE): A randomized clinical trial in dogs with mammary carcinoma. Anticancer Research 1998, 18:1015-1020.
68. Uva P., Aurisicchio L., Watters J., Loboda A., Kulkami A., Castle J., Palombo F., Viti V., Mesiti G., Zappulli V., Marconato L., Abramo F., Ciliberto G., Lahm A., Monica N., Rinaldis E. Comparative expression pathway analysis of human and canine mammary tumors. BMC Genomics 2009, 10:135-155.
69. Webster J.D., Dennis M.M., Dervisis N., Heller J., Bacon N.J., Bergman P.J., Bienzle D., Cassali G., Castagnaro M., Cullen J., Esplin D.G., Peña L., Goldschmidt M.H., Hahn K.A., Henry C.J., Hellmén E., Kamstock D., Kirpensteijn J., Kitchell B.E., Amorim R.L., Lenz S.D., Lipscomb T.P., McEntee M., McGill L.D., McKnight C.A., McManus P.M., Moore A.S., Moore P.F., Moroff S.D., Nakayama H., Northrup N.C., Sarli G., Scase T., Sorenmo K., Schulman F.Y., Shoieb A.M., Smedley R.C., Spangler W.L., Teske E., Thamm D.H., Valli V.E., Vernau W., von Euler H., Withrow S.J., Weisbrode S.E., Yager J., Kiupel M. Recommended guidelines for the conduct and evaluation of prognostic studies in veterinary oncology. Veterinary Pathology 2011, 48:7-18.
70. Withrow S.J. Why worry about cancer in pets?. Small Animal Clinical Oncology 2007, xv. Saunders Elsevier, St. Louis, MO, USA. Fourth Ed.
71. Yamagami T., Kobayashi T., Takahashi K., Sugiyama M. Prognosis for canine mammary tumours based on TNM and histologic classification. Journal of Veterinary Medical Science 1996, 58:1079-1083.
72. Yamagami T., Kobayashi T., Takahashi K., Sugiyama M. Influence of ovariectomy at the time of mastectomy on the prognosis for canine malignant mammary tumours. Journal of Small Animal Practice 1996, 37:462-464.
73. Yan P.S., Venkataramu C., Ibrahim A., Liu J.C., Shen R.Z., Diaz N.M., Centeno B., Weber F., Leu Y.W., Shapiro C.L., Eng C., Yeatman T.J., Huang T.H. Mapping geographic zones of breast cancer risk with epigenetic biomarkers in normal breast tissue. Clinical Cancer Research 2006, 12:6626-6636.
74. Zacchetti A., van Garderen E., Rutteman G.R. Immunohistochemical evaluation of p53 expression with different antibodies in malignant canine tumours with or without p53 gene mutation. Veterinary Comparative Oncology 2007, 5:108-118.
75. Zsikla V., Baumann M., Cathomas G. Effect of buffered formalin on amplification of DNA from paraffin wax embedded small biopsies using real-time PCR. Journal of Clinical Pathology 2004, 57:654-656.